SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Apimeds Pharmaceuticals US, Inc (APUS) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -218.14%.
Criteria proven by this page:
- VALUE (100/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
- Trailing Earnings Yield -218.14% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 27/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — APUS
Valuation Multiples
P/E (TTM)-0.5
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.29
P/S Ratio0.00
EV/EBITDA0.8
Per Share Data
EPS (TTM)$-4.10
Book Value / Share$6.49
Revenue / Share$0.00
FCF / Share$-4.17
Yields & Fair Value
Earnings Yield-218.14%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2021 |
-2.5 |
0.00 |
-10.63 |
0.00 |
- |
| 2022 |
-3.8 |
0.11 |
-3.55 |
0.00 |
- |
| 2023 |
-3.3 |
-0.20 |
79.57 |
0.00 |
- |
| 2024 |
-1.8 |
-0.02 |
-1.87 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2021 |
$-0.08 |
$0.00 |
$-1.03M |
- |
| 2022 |
$-0.05 |
$0.00 |
$-668.67K |
- |
| 2023 |
$-0.06 |
$0.00 |
$-777.69K |
- |
| 2024 |
$-0.11 |
$0.00 |
$-1.39M |
- |
